Impact of COVID-19 Towards Antibiotics Consumption in Hospital Queen Elizabeth II

Abstract

The COVID-19 pandemic has disrupted antimicrobial stewardship (AMS) activities in Hospital Queen Elizabeth II (HQEII), which has led to a surge in antibiotics consumption, particularly meropenem, vancomycin, piperacillin-tazobactam, ceftazidime, and ceftriaxone. This study aimed to compare the prevalence of antibiotics consumption in HQEII before (2018/2019) and during (2020/2021) the pandemic to explore its impact on antibiotic costs and bacterial resistance.